Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest in USD of Inmune Bio, Inc. from Q4 2020 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
Summary
Inmune Bio, Inc. quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest history and change rate from Q4 2020 to Q2 2023.
  • Inmune Bio, Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest for the quarter ending 30 Jun 2023 was $50.7M, a 27.6% decline year-over-year.
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Quarterly (USD)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, YoY Quarterly Change (%)

Inmune Bio, Inc. Quarterly Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest (USD)

Period Value YoY Chg Change % Date Report Filed
Q2 2023 $50.7M -$19.3M -27.6% 30 Jun 2023 10-Q 07 Aug 2023
Q1 2023 $55.3M -$20.3M -26.9% 31 Mar 2023 10-Q 03 May 2023
Q4 2022 $60.1M -$20.1M -25.1% 31 Dec 2022 10-Q 07 Aug 2023
Q3 2022 $63.7M 30 Sep 2022 10-Q 02 Nov 2022
Q2 2022 $69.9M 30 Jun 2022 10-Q 03 Aug 2022
Q1 2022 $75.6M 31 Mar 2022 10-Q 05 May 2022
Q4 2021 $80.2M +$41.5M +107% 31 Dec 2021 10-K 02 Mar 2023
Q4 2020 $38.8M 31 Dec 2020 10-K 03 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.